top of page
Medical Checkup

TRANSFORM

Trial Enrolment Status

OPEN

Disease Under Study

Idiopathic Pulmonary Fibrosis

Duration

~35 Weeks

About the Trial

Idiopathic Pulmonary Fibrosis is a chronic lung disease which causes scarring of the lungs and difficulty in breathing. GSK3915393 is a new medicine, which is being tested in participants with IPF for the first time. The study will assess the safety and effectiveness of GSK3915393 in IPF participants.

Mechanism of Action:

Dr. George Philteos

Principal Investigator

Dr. George Philteos

Sub-Investigator

Dr. Anushya Chelvanathan

Study Coordinator

Asvini Kulasingham, RRT

bottom of page